Brought to you by 
Inhale, Pharmacia develop PEGylated RA drug
23 Jul 2002
Executive Summary
Inhale Therapeutic Systems (drug delivery) has licensed its Shearwater subsidiary's PEGylation technology to Pharmacia for use with CDP870, an antibody fragment that just completed Phase II clinical trials to treat rheumatoid arthritis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Inhale, Pharmacia develop PEGylated RA drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice